Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
DL3-H52Hy | Human | Human DLL3 (176-492) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
DL3-H52Hz | Human | Human DLL3 (312-492) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
DL3-H52Ha | Human | Human DLL3 (353-492) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
DL3-M53H9 | Mouse | Mouse DLL3 Protein, His Tag | ![]() |
||
DL3-H82F5 | Human | Biotinylated Human DLL3 Protein, Fc,Avitag™ | ![]() |
||
DL3-H82E4 | Human | Biotinylated Human DLL3 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
DL3-R52H4 | Rhesus macaque | Rhesus macaque DLL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
DL3-R52H3 | Rat | Rat DLL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
DL3-HF2H4 | Human | FITC-Labeled Human DLL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
DL3-HF253 | Human | FITC-Labeled Human DLL3 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
DL3-C52H3 | Cynomolgus | Cynomolgus DLL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
DL3-H52H4 | Human | Human DLL3 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
DL3-H5255 | Human | Human DLL3 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human DLL3 (312-492) , His Tag (Cat. No. DL3-H52Hz) at 1 μg/mL (100 μL/well) can bind Anti-DLL3 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
The purity of Biotinylated Human DLL3, His,Avitag (Cat. No. DL3-H82E4) is more than 90% and the molecular weight of this protein is around 51-69 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
HPN-328 | HPN-328 | Phase 2 Clinical | Harpoon Therapeutics | Small Cell Lung Carcinoma | Details |
Tarlatamab | AMG-757 | Phase 2 Clinical | Amgen Inc | Small Cell Lung Carcinoma; Prostatic Neoplasms | Details |
Rovalpituzumab tesirine | SC0001SCX; SC16LD6.5; SC0001-SCX; SC-0002; P256HB60FF | Phase 1 Clinical | Abbvie Inc, Stemcentrx | Solid tumours; Small Cell Lung Carcinoma; Glioblastoma; Medullary thyroid cancer (MTC); Prostatic Neoplasms; Carcinoma, Neuroendocrine; Melanoma | Details |
This web search service is supported by Google Inc.